KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Xavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, Mark S Freedman, Till Sprenger, Robert J Fox, Eva Kubala Havrdova, Fred Lublin, Dan Huang, Nandini Raghavan, Janice Wong, Andrea Vaclavkova, Jelena Dukovski, Philippe Linscheid, Michel Burcklen, Ludwig Kappos

J Neurol 273(4) 234

PMID41879928
PMCIDPMC13018072
DOI10.1007/s00415-026-13675-7
发表日期2026-03-25
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线;Fig. 4:图注未提示 KM 曲线;Fig. 5:图注未提示 KM 曲线。
摘要

摘要

INTRODUCTION: In phase 3 OPTIMUM study, ponesimod demonstrated superior efficacy and acceptable safety vs teriflunomide in participants with relapsing multiple sclerosis (RMS). This long-term extension (LTE) study was designed to assess the safety and efficacy of ponesimod 20 mg (P20 mg) during extended treatment. METHODS: Participants who completed core OPTIMUM study entered OPTIMUM-LTE; Participants receiving P20 mg once daily (OD) in core continued with the same dose (P20 mg/P20 mg) and those receiving teriflunomide 14 mg OD switched to P20 mg (T14 mg/P20 mg) in the LTE study. Safety assessments included treatment-emergent adverse events (TEAE). Efficacy was assessed using annualized relapse rate (ARR), time to first confirmed relapse up to end of study (EOS), confirmed disability accumulation (CDA), and magnetic resonance imaging (MRI)-based endpoints. RESULTS: Of 1133 participants from core study, 877 were enrolled in 240-week LTE study (ponesimod: 439; teriflunomide:438). During LTE, 93.6% of participants in both groups experienced ≥ 1 TEAE; overall, serious TEAEs were experienced by 12.9% of participants (P20 mg/P20 mg: 12.8%; T14 mg/P20 mg: 13.0%) and TEAEs leading to study treatment discontinuation were experienced by 8.6% of participants (P20 mg/P20 mg: 7.7%; T14 mg/P20 mg: 9.4). In combined analysis period, mean ARR was 0.143 (95% CL: 0.123-0.167) for P20 mg/P20 mg and 0.184 (95% CL: 0.158-0.213) for T14 mg/P20 mg; 44.3% of participants in P20 mg/P20 mg and 49.5% in T14 mg/P20 mg experienced relapse. Overall, more participants in P20 mg/P20 mg vs T14 mg/P20 mg group achieved no evidence of disease activity (NEDA)-3 at end of LTE (17.5% vs 7.5%). CONCLUSIONS: Ponesimod demonstrated extended safety and sustained efficacy over 5 years in participants with RMS, without new safety signals. Results suggest that the effects on the MS disease control are maintained with ponesimod over the LTE treatment period.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Annualized relapse rates over time in the P20 mg/P20 mg and T14 mg/P20 mg groups. EOS is defined as end of extension study or cut-off date. 24-week period is calculated relative to randomization in the core study or core EOS/extension study start as applicable. The last interval 'Week 216—EOS' can be longer than 24 weeks. It contains relapse from extension week 216 to EOS for all participants (including the Ukrainian participants where extended treatment periods were allowed). All participants (including participants randomized to Teriflunomide treatment group at core study) received ponesimod 20 mg in Extension analysis period. ARR, annualized relapse rate
非 KM Figure
Fig. 2Time to first confirmed relapse (weeks). All participants (including participants randomized to the Teriflunomide treatment group at the core study) received ponesimod 20 mg in the Extension analysis period
非 KM Figure
Fig. 3Change in EDSS score over time. All participants (including participants randomized to Teriflunomide treatment group at core study) received ponesimod 20 mg in Extension analysis period. Intervals up to the time point where there were at least 5 participants of each arm. The Extension Week 240 contains data of this visit of Ukrainian participants with allowed extended treatment time and data of EOT visit planned at week 240 of other participants. The Extension EOT visit contains data of all EOT visits of treatment completers and participants with early treatment discontinuation irrespective of time of discontinuation. The post-week 240 visits include Ukrainian participants only. EDSS Expanded disability status scale, SE standard error
非 KM Figure
Fig. 4Changes in CUALs over time. All participants (including participants randomized to Teriflunomide treatment group at core study) received ponesimod 20 mg in the Extension analysis period. A negative binomial model without offset is applied with Wald confidence intervals. The Extension Week 240 contains data of this visit of Ukrainian participants with allowed extended treatment time and data of the EOT visit planned at week 240 of other participants. The Extension EOT visit contains data of all EOT visits of treatment completers and participants with early treatment discontinuation. The post-week 240 visits are applicable for Ukrainian participants only. CUALS Combined unique active lesions
非 KM Figure
Fig. 5Changes in brain volume over time. All participants (including participants randomized to the Teriflunomide treatment group at the core study) received ponesimod 20 mg in the Extension analysis period. Intervals up to the time point where there are at least 5 participants in each arm. The Extension Week 240 contains data of this visit of Ukrainian participants with allowed extended treatment time and data of the EOT visit planned at week 240 of other participants. The Extension EOT visit contains data of all EOT visits of treatment completers and participants with early treatment discontinuation. The post-week 240 visits are applicable for Ukrainian participants only
非 KM Figure